A significant difference in the progression-free survival and overall survival in the NSCLC patients with high P2X7 expression was identified, when compared with that of patients with low expression (P=0.03 and P=0.02, respetively). The gene discussed is P2RX7; the disease is non-small cell lung carcinoma.